Longitudinal outcomes in a cohort of ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of Malaria

Clinical Infectious Diseases

Volumn 59, Issue 4, 2014, Pages 509-516

  Wanzira, Humphrey ^a   Kakuru, Abel ^a   Arinaitwe, Emmanuel ^a   Bigira, Victor ^a   Muhindo, Mary K ^a   Conrad, Melissa ^b   Rosenthal, Philip J ^b   Kamya, Moses R ^c   Tappero, Jordan W ^d   Dorsey, Grant ^b  

^a INFECTIOUS DISEASES RESEARCH COLLABORATION   (Uganda)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Artemether lumefantrine; Cohort; Dihydroartemisinin piperaquine; Malaria; Uganda

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; COTRIMOXAZOLE; DIHYDROARTEMISININ PLUS PIPERAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; PIPERAQUINE; QUINOLINE DERIVATIVE;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; CHILD; CHILD HOSPITALIZATION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFANT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT INFECTION; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; UGANDA; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; HOSPITALIZATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA, FALCIPARUM; PRESCHOOL CHILD; PROCEDURES; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA; TIME;

ANTIMALARIALS; ARTEMISININS; CHILD, PRESCHOOL; COHORT STUDIES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FLUORENES; HIV INFECTIONS; HOSPITALIZATION; HUMANS; INFANT; LONGITUDINAL STUDIES; MALARIA, FALCIPARUM; MALE; QUINOLINES; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; UGANDA;

EID: 84904280797     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu353     Document Type: Article

References (18)

1. World Health Organization. Guidelines for the treatment of malaria, 2nd ed. Geneva, Switzerland: WHO, 2010.
2. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 2009; 3:CD007483.
3. The Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med 2011; 8:e1001119.
4. Arinaitwe E, Sandison TG, Wanzira H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 2009; 49: 1629-37.
5. Yeka A, Dorsey G, Kamya MR, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One 2008; 3:e2390.
6. Zongo I, Dorsey G, Rouamba N, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 2007; 45: 1453-61.
7. Price RN, Dorsey G, Ashley EA, et al. World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs. Malar J 2007; 6: 119.
8. Okello PE, Van Bortel W, Byaruhanga AM, et al. Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg 2006; 75: 219-25.
9. Greenhouse B, Myrick A, Dokomajilar C, et al. Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am J Trop Med Hyg 2006; 75: 836-42.
10. Bukirwa H, Yeka A, Kamya MR, et al. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials 2006; 1:e7.
11. Sandison TG, Homsy J, Arinaitwe E, et al. Protective efficacy of cotrimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ 2011; 342:d1617.
12. World Health Organization. Global AMDP database - WHO African region. Available at: http://www.who.int/malaria/am-drug-policies-by-region-afro/en/ index.html. Accessed 15 December 2013.
13. Dorsey G, Staedke S, Clark TD, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 2007; 297: 2210-9.
14. Mutabingwa TK, Anthony D, Heller A, et al. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005; 365: 1474-80.
15. Kamya MR, Yeka A, Bukirwa H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials 2007; 2:e20.
16. Katrak S, Gasasira A, Arinaitwe E, et al. Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Malar J 2009; 8: 272.
17. Stepniewska K, White NJ. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother 2008; 52: 1589-96.
18. Tarning J, Ashley EA, Lindegardh N, et al. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin- piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother 2008; 52: 1052-61.